Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Neoplasia (New York, N.Y.)|December 29, 2018
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander EffectCho Rong Hong, William R Wilson, Kevin O HicksAdvances in Experimental Medicine and Biology|June 22, 2016
Efficient Protocol for the Identification of Hypoxic Cell RadiosensitisersCho Rong Hong, Jingli Wang, Kevin O Hicks, et al.Bioorganic & Medicinal Chemistry|March 22, 2014
Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisersMuriel Bonnet, Cho Rong Hong, Yongchuan Gu, et al.Biochemical Pharmacology|August 23, 2018
Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effectsCho Rong Hong, Benjamin D Dickson, Jagdish K Jaiswal, et al.Cancer Chemotherapy and Pharmacology|July 10, 2021
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrugCho Rong Hong, Sunali Y Mehta, H D Sarath Liyanage, et al.Journal of Medicinal Chemistry|December 19, 2017
Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole AlkylsulfonamidesMuriel Bonnet, Cho Rong Hong, Way Wua Wong, et al.Molecular Pharmacology|April 14, 2019
Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of EvofosfamideFrancis W Hunter, Jules B L Devaux, Fanying Meng, et al.Pageof 1